- Home
- DVAX vs KLTOW Comparison
DVAX vs KLTOW Comparison
Compare DVAX & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- KLTOW
- Stock Information
- Founded
- DVAX 1996
- KLTOW N/A
- Country
- DVAX United States
- KLTOW United States
- Employees
- DVAX N/A
- KLTOW 3
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DVAX Health Care
- KLTOW Health Care
- Exchange
- DVAX Nasdaq
- KLTOW Nasdaq
- Market Cap
- DVAX N/A
- KLTOW N/A
- IPO Year
- DVAX 2004
- KLTOW 2022
- Fundamental
- Price
- DVAX $9.51
- KLTOW $0.02
- Analyst Decision
- DVAX Buy
- KLTOW
- Analyst Count
- DVAX 4
- KLTOW 0
- Target Price
- DVAX $26.25
- KLTOW N/A
- AVG Volume (30 Days)
- DVAX 2.6M
- KLTOW N/A
- Earning Date
- DVAX 05-06-2025
- KLTOW N/A
- Dividend Yield
- DVAX N/A
- KLTOW N/A
- EPS Growth
- DVAX N/A
- KLTOW N/A
- EPS
- DVAX N/A
- KLTOW N/A
- Revenue
- DVAX $294,620,000.00
- KLTOW N/A
- Revenue This Year
- DVAX $21.18
- KLTOW N/A
- Revenue Next Year
- DVAX $16.57
- KLTOW N/A
- P/E Ratio
- DVAX N/A
- KLTOW N/A
- Revenue Growth
- DVAX 24.76
- KLTOW N/A
- 52 Week Low
- DVAX $9.74
- KLTOW N/A
- 52 Week High
- DVAX $14.63
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- DVAX 32.12
- KLTOW N/A
- Support Level
- DVAX $9.22
- KLTOW N/A
- Resistance Level
- DVAX $10.16
- KLTOW N/A
- Average True Range (ATR)
- DVAX 0.47
- KLTOW 0.00
- MACD
- DVAX -0.08
- KLTOW 0.00
- Stochastic Oscillator
- DVAX 11.37
- KLTOW 0.00
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.